Individual Approach in Gynecological Cancer Brachytherapy

Not Applicable

• Conditions: Cancer
• Interventions: Other: 3D printed applicator

• Registration Number: NCT03466957
• Lead Sponsor: Institute of Oncology Ljubljana

Brief Summary

MRI guided adaptive brachytherapy (BT) represents the gold standard in the treatment of gynecological cancers. Commercially available standard MRI compatible applicators for BT of gynecological cancers don't always allow for optimal target volume coverage. Three-dimensional (3D) printed technology enables versatile possibilities of improvement of standard applicators and development of novel applicators with better coverage of the target volume. The purpose of this study is to implement and assess 3D printing technology as an instrument for designing and manufacturing applicators for individualized BT of gynecological cancers.

Detailed Description

Patients with locoregionally gynecological cancers will be included in this single-institution, non-randomized, one-arm study. All patients will receive 45-50 Gy external beam radiotherapy (EBRT) with intensity-modulated radiotherapy/volumetric-modulated arc therapy (IMRT/VMAT) technique, 1.8-2 Gy/fraction +/- concurrent cisplatin based chemotherapy. First BT with commercially available standard applicators (tandem with ring +/- parallel needles or vaginal cylinder) will be carried out. MRI with applicator in situ will be performed, high-risk clinical target volume (CTV-HR) and organs at risk (OAR) will be delineated and treatment planning will be conducted. In the case of large gynecological cancer and suboptimal target coverage at BT (V100 ≤ 90%, D98 ≤ 80%, D90 ≤ 100%, D100 ≤ 60%) a preplan will be performed as the basis for the 3D applicator modelling. The next BT application will be performed with an individually designed 3D printed applicator. Dose-volume characteristics of the following treatment plans will be compared: the preplan, the plan with standard and the plan with individual 3D printed applicator.

The primary objective of the study is to determine the improvement of dose-volume parameters with the use of 3D printed individual applicators in advanced gynecological cancer.

Study Timeline

• Study Start: 2016-05
• Status Verified: 2018-03
• Study First Submitted: 2018-03-01
• Study First Submitted QC: 2018-03-14
• Last Update Submitted: 2018-03-14
• Study First Posted: 2018-03-15
• Last Update Posted: 2018-03-15
• Primary Completion: 2018-05
• Study Completion: 2019-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 13

Inclusion Criteria

• patients with locally advanced gynecological cancer (cervical, uterine, vaginal, vulvar cancer) eligible for treatment with brachytherapy
• squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma, histologically proven
• patients fit for regional or general anesthesia
• signed written informed consent

Exclusion Criteria

• regional or general anesthesia contraindications
• contraindications for MRI

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
3D printed applicator	3D printed applicator	individually designed applicator for BT

Primary Outcome Measures

Name	Time	Method
target volume CTV-HR	at two hours after the end of brachytherapy procedure	V100 (%), D90 (%), D98 (%), D100 (%)

Secondary Outcome Measures

Name	Time	Method
organs at risk	at two hours after the end of brachytherapy procedure	D2cc (Gy), D0.1cc (Gy), Dmax (Gy)

Trial Locations

Locations (1)

Institute of Oncology Ljubljana; 🇸🇮 Ljubljana, Slovenia